Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study
Summary Objective We have previously reported a new luteal‐phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to systematically assess the efficiency and safety of this strategy by comparing it with conventional ovarian stimulation protocols. Design Ret...
Saved in:
| Published in | Clinical endocrinology (Oxford) Vol. 84; no. 5; pp. 720 - 728 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.05.2016
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0300-0664 1365-2265 |
| DOI | 10.1111/cen.12983 |
Cover
Loading…
| Abstract | Summary
Objective
We have previously reported a new luteal‐phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to systematically assess the efficiency and safety of this strategy by comparing it with conventional ovarian stimulation protocols.
Design
Retrospective cohort study.
Subjects
Patients with normal ovarian reserve undergoing ovum pick‐up (OPU) cycles between April 2012 and September 2013 were enrolled: 708 patients underwent the LPS protocol compared with 745 patients who underwent the mild treatment protocol and 1287 patients who underwent the short‐term protocol.
Measurements
Number of mature oocytes retrieved and top‐quality embryos obtained, implantation rate, pregnancy rate, live birth and ongoing pregnancy rate and neonatal outcomes.
Results
The numbers of mature oocytes retrieved and top‐quality embryos obtained per OPU cycle were significantly increased in the LPS group (10·9 ± 7·6 and 4·6 ± 4·3, respectively) compared with the mild treatment group (3·7 ± 3·0 and 1·8 ± 1·8, respectively, both P < 0·001) or the short‐term group (9·1 ± 5·5 and 3·7 ± 3·1, respectively, both P < 0·001). Moreover, the total gonadotrophin used was also the highest in the LPS group. No significant differences were identified in the implantation rate (35·5% vs 34·8%, P > 0·05), pregnancy rate (46·2% vs 43·7%, P > 0·05) or live birth and ongoing pregnancy rate (44·4% vs 41·7%, P > 0·05) per frozen‐thawed embryo transfer (FET) cycle in the LPS and mild treatment groups, respectively. However, the LPS protocol achieved a higher implantation rate (35·5% vs 31·8%, P = 0·012), pregnancy rate (46·2% vs 41·9%, P = 0·041), and live birth and ongoing pregnancy rate (44·4% vs 39·2%, P = 0·012) compared with the short‐term protocol. Neonatal outcomes in the LPS group were similar to the other two groups.
Conclusions
The available data suggest that LPS is a feasible strategy for infertility treatment and complements the available follicular‐phase ovarian stimulation strategies. |
|---|---|
| AbstractList | OBJECTIVEWe have previously reported a new luteal-phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to systematically assess the efficiency and safety of this strategy by comparing it with conventional ovarian stimulation protocols.DESIGNRetrospective cohort study.SUBJECTSPatients with normal ovarian reserve undergoing ovum pick-up (OPU) cycles between April 2012 and September 2013 were enrolled: 708 patients underwent the LPS protocol compared with 745 patients who underwent the mild treatment protocol and 1287 patients who underwent the short-term protocol.MEASUREMENTSNumber of mature oocytes retrieved and top-quality embryos obtained, implantation rate, pregnancy rate, live birth and ongoing pregnancy rate and neonatal outcomes.RESULTSThe numbers of mature oocytes retrieved and top-quality embryos obtained per OPU cycle were significantly increased in the LPS group (10·9 ± 7·6 and 4·6 ± 4·3, respectively) compared with the mild treatment group (3·7 ± 3·0 and 1·8 ± 1·8, respectively, both P < 0·001) or the short-term group (9·1 ± 5·5 and 3·7 ± 3·1, respectively, both P < 0·001). Moreover, the total gonadotrophin used was also the highest in the LPS group. No significant differences were identified in the implantation rate (35·5% vs 34·8%, P > 0·05), pregnancy rate (46·2% vs 43·7%, P > 0·05) or live birth and ongoing pregnancy rate (44·4% vs 41·7%, P > 0·05) per frozen-thawed embryo transfer (FET) cycle in the LPS and mild treatment groups, respectively. However, the LPS protocol achieved a higher implantation rate (35·5% vs 31·8%, P = 0·012), pregnancy rate (46·2% vs 41·9%, P = 0·041), and live birth and ongoing pregnancy rate (44·4% vs 39·2%, P = 0·012) compared with the short-term protocol. Neonatal outcomes in the LPS group were similar to the other two groups.CONCLUSIONSThe available data suggest that LPS is a feasible strategy for infertility treatment and complements the available follicular-phase ovarian stimulation strategies. We have previously reported a new luteal-phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to systematically assess the efficiency and safety of this strategy by comparing it with conventional ovarian stimulation protocols. Retrospective cohort study. Patients with normal ovarian reserve undergoing ovum pick-up (OPU) cycles between April 2012 and September 2013 were enrolled: 708 patients underwent the LPS protocol compared with 745 patients who underwent the mild treatment protocol and 1287 patients who underwent the short-term protocol. Number of mature oocytes retrieved and top-quality embryos obtained, implantation rate, pregnancy rate, live birth and ongoing pregnancy rate and neonatal outcomes. The numbers of mature oocytes retrieved and top-quality embryos obtained per OPU cycle were significantly increased in the LPS group (10·9 ± 7·6 and 4·6 ± 4·3, respectively) compared with the mild treatment group (3·7 ± 3·0 and 1·8 ± 1·8, respectively, both P < 0·001) or the short-term group (9·1 ± 5·5 and 3·7 ± 3·1, respectively, both P < 0·001). Moreover, the total gonadotrophin used was also the highest in the LPS group. No significant differences were identified in the implantation rate (35·5% vs 34·8%, P > 0·05), pregnancy rate (46·2% vs 43·7%, P > 0·05) or live birth and ongoing pregnancy rate (44·4% vs 41·7%, P > 0·05) per frozen-thawed embryo transfer (FET) cycle in the LPS and mild treatment groups, respectively. However, the LPS protocol achieved a higher implantation rate (35·5% vs 31·8%, P = 0·012), pregnancy rate (46·2% vs 41·9%, P = 0·041), and live birth and ongoing pregnancy rate (44·4% vs 39·2%, P = 0·012) compared with the short-term protocol. Neonatal outcomes in the LPS group were similar to the other two groups. The available data suggest that LPS is a feasible strategy for infertility treatment and complements the available follicular-phase ovarian stimulation strategies. Summary Objective We have previously reported a new luteal-phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to systematically assess the efficiency and safety of this strategy by comparing it with conventional ovarian stimulation protocols. Design Retrospective cohort study. Subjects Patients with normal ovarian reserve undergoing ovum pick-up (OPU) cycles between April 2012 and September 2013 were enrolled: 708 patients underwent the LPS protocol compared with 745 patients who underwent the mild treatment protocol and 1287 patients who underwent the short-term protocol. Measurements Number of mature oocytes retrieved and top-quality embryos obtained, implantation rate, pregnancy rate, live birth and ongoing pregnancy rate and neonatal outcomes. Results The numbers of mature oocytes retrieved and top-quality embryos obtained per OPU cycle were significantly increased in the LPS group (10·9 ± 7·6 and 4·6 ± 4·3, respectively) compared with the mild treatment group (3·7 ± 3·0 and 1·8 ± 1·8, respectively, both P < 0·001) or the short-term group (9·1 ± 5·5 and 3·7 ± 3·1, respectively, both P < 0·001). Moreover, the total gonadotrophin used was also the highest in the LPS group. No significant differences were identified in the implantation rate (35·5% vs 34·8%, P > 0·05), pregnancy rate (46·2% vs 43·7%, P > 0·05) or live birth and ongoing pregnancy rate (44·4% vs 41·7%, P > 0·05) per frozen-thawed embryo transfer (FET) cycle in the LPS and mild treatment groups, respectively. However, the LPS protocol achieved a higher implantation rate (35·5% vs 31·8%, P = 0·012), pregnancy rate (46·2% vs 41·9%, P = 0·041), and live birth and ongoing pregnancy rate (44·4% vs 39·2%, P = 0·012) compared with the short-term protocol. Neonatal outcomes in the LPS group were similar to the other two groups. Conclusions The available data suggest that LPS is a feasible strategy for infertility treatment and complements the available follicular-phase ovarian stimulation strategies. Summary Objective We have previously reported a new luteal‐phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to systematically assess the efficiency and safety of this strategy by comparing it with conventional ovarian stimulation protocols. Design Retrospective cohort study. Subjects Patients with normal ovarian reserve undergoing ovum pick‐up (OPU) cycles between April 2012 and September 2013 were enrolled: 708 patients underwent the LPS protocol compared with 745 patients who underwent the mild treatment protocol and 1287 patients who underwent the short‐term protocol. Measurements Number of mature oocytes retrieved and top‐quality embryos obtained, implantation rate, pregnancy rate, live birth and ongoing pregnancy rate and neonatal outcomes. Results The numbers of mature oocytes retrieved and top‐quality embryos obtained per OPU cycle were significantly increased in the LPS group (10·9 ± 7·6 and 4·6 ± 4·3, respectively) compared with the mild treatment group (3·7 ± 3·0 and 1·8 ± 1·8, respectively, both P < 0·001) or the short‐term group (9·1 ± 5·5 and 3·7 ± 3·1, respectively, both P < 0·001). Moreover, the total gonadotrophin used was also the highest in the LPS group. No significant differences were identified in the implantation rate (35·5% vs 34·8%, P > 0·05), pregnancy rate (46·2% vs 43·7%, P > 0·05) or live birth and ongoing pregnancy rate (44·4% vs 41·7%, P > 0·05) per frozen‐thawed embryo transfer (FET) cycle in the LPS and mild treatment groups, respectively. However, the LPS protocol achieved a higher implantation rate (35·5% vs 31·8%, P = 0·012), pregnancy rate (46·2% vs 41·9%, P = 0·041), and live birth and ongoing pregnancy rate (44·4% vs 39·2%, P = 0·012) compared with the short‐term protocol. Neonatal outcomes in the LPS group were similar to the other two groups. Conclusions The available data suggest that LPS is a feasible strategy for infertility treatment and complements the available follicular‐phase ovarian stimulation strategies. |
| Author | Chen, Qiuju Lyu, Qifeng Ai, Ai Fu, Yonglun Wang, Ningling Wang, Yun Tian, Hui Dong, Jing Kuang, Yanping |
| Author_xml | – sequence: 1 givenname: Ningling surname: Wang fullname: Wang, Ningling organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 2 givenname: Yun surname: Wang fullname: Wang, Yun organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 3 givenname: Qiuju surname: Chen fullname: Chen, Qiuju organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 4 givenname: Jing surname: Dong fullname: Dong, Jing organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 5 givenname: Hui surname: Tian fullname: Tian, Hui organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 6 givenname: Yonglun surname: Fu fullname: Fu, Yonglun organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 7 givenname: Ai surname: Ai fullname: Ai, Ai organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 8 givenname: Qifeng surname: Lyu fullname: Lyu, Qifeng organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China – sequence: 9 givenname: Yanping surname: Kuang fullname: Kuang, Yanping email: kuangyanp@126.com organization: Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26603821$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90c1u1DAQB3ALFdFt4cALIEtc4JDWH4ntcEOrtlRaFYSgPVqOM2FdsnGwnS37Njwq7m5boQrwxbb0-4_lmQO0N_gBEHpJyRHN69jCcERZrfgTNKNcVAVjotpDM8IJKYgQ5T46iPGaEFIpIp-hfSYE4YrRGfq1mBKYvhiXJgL2axOcGXBMbjX1Jjk_4HXE1g9rGG5vpv-rcQMe8ymbiG9cWuLBh9UfNkCEsAacApgELe58wOeXp--wwb0J3yCDFHwcwSaXmfVLH1J-YWo3z9HTzvQRXtzth-jr6cmX-Ydi8fHsfP5-UVheU15IAbKxppSq6UCqztZMQKcaZRgVTNSmbbpSEWZaVVlQqqtUaeqWVrY2vGo4P0RvdnXH4H9MEJNeuWih780AfoqaSlkTRuuyyvT1I3rtp5B7s1WKEsoYy-rVnZqaFbR6DG5lwkbf9z6Dtztg89djgO6BUKJv56rzXPV2rtkeP7LWpW3vUzCu_1_ixvWw-XdpPT-5uE8Uu4SLCX4-JEz4roXkstJXF2eaS_Xp8yUV-or_BsT2xi8 |
| CitedBy_id | crossref_primary_10_1186_s12905_022_02126_w crossref_primary_10_1093_humrep_deaa203 crossref_primary_10_1016_j_rbmo_2019_03_212 crossref_primary_10_1007_s11596_022_2687_0 crossref_primary_10_1097_GCO_0000000000000452 crossref_primary_10_3390_life10060090 crossref_primary_10_1007_s10815_019_01607_6 crossref_primary_10_1186_s12958_017_0291_0 crossref_primary_10_1093_humupd_dmz037 crossref_primary_10_1038_s41598_017_07773_w crossref_primary_10_1007_s00404_025_07934_7 crossref_primary_10_1038_s41598_017_08805_1 crossref_primary_10_1016_j_rbmo_2024_103889 crossref_primary_10_1093_humrep_dey217 crossref_primary_10_1093_humupd_dmw047 crossref_primary_10_3389_fendo_2021_636038 crossref_primary_10_3389_fendo_2021_801026 crossref_primary_10_1186_s43043_024_00166_w crossref_primary_10_3389_fendo_2023_1117513 crossref_primary_10_1097_MD_0000000000011906 crossref_primary_10_1016_j_rbmo_2022_04_007 crossref_primary_10_3389_fphys_2020_01102 crossref_primary_10_1016_j_rbmo_2020_05_002 crossref_primary_10_17816_KMJ2022_568 crossref_primary_10_1016_j_rbmo_2024_104121 crossref_primary_10_1016_j_rbmo_2019_03_101 crossref_primary_10_3389_fendo_2018_00317 crossref_primary_10_1007_s10815_019_01638_z crossref_primary_10_1007_s13224_022_01703_1 crossref_primary_10_2217_fon_2016_0161 crossref_primary_10_1007_s10815_020_01966_5 crossref_primary_10_1016_j_ejogrb_2023_12_035 crossref_primary_10_1093_humupd_dmaa040 crossref_primary_10_1007_s12325_018_0713_1 crossref_primary_10_1093_humrep_deaa068 crossref_primary_10_26442_20795696_2022_5_201675 crossref_primary_10_1016_j_biosystems_2021_104558 crossref_primary_10_1007_s10815_021_02237_7 crossref_primary_10_1007_s00404_020_05568_5 crossref_primary_10_1111_jog_14871 crossref_primary_10_1016_j_fertnstert_2020_07_008 crossref_primary_10_3390_medicina55030068 crossref_primary_10_1016_j_rbmo_2018_07_006 crossref_primary_10_1210_clinem_dgae847 crossref_primary_10_1111_aogs_15059 crossref_primary_10_1007_s11596_018_1908_z crossref_primary_10_1210_clinem_dgad397 crossref_primary_10_1016_j_rbmo_2022_03_003 crossref_primary_10_1186_s12958_018_0335_0 crossref_primary_10_1097_GCO_0000000000000869 crossref_primary_10_1186_s13048_020_00620_z crossref_primary_10_1016_j_jogoh_2018_11_003 crossref_primary_10_1007_s00404_018_4856_8 crossref_primary_10_1016_j_rbmo_2023_103305 crossref_primary_10_5005_jp_journals_10016_1206 crossref_primary_10_1186_s12905_023_02327_x crossref_primary_10_5301_tj_5000586 crossref_primary_10_1186_s12958_019_0518_3 crossref_primary_10_1016_j_rbmo_2024_104383 crossref_primary_10_1016_j_fertnstert_2017_05_027 crossref_primary_10_3390_jcm11206151 crossref_primary_10_3389_fendo_2019_00094 crossref_primary_10_3724_zdxbyxb_2023_0533 crossref_primary_10_1080_09513590_2018_1435636 crossref_primary_10_1007_s11427_019_9526_2 crossref_primary_10_3389_fendo_2022_979934 crossref_primary_10_17116_repro201622443_46 crossref_primary_10_1080_09513590_2020_1822804 |
| Cites_doi | 10.1210/jcem-64-4-675 10.1093/humupd/dmn056 10.1210/jc.2002-020788 10.3389/fnins.2013.00099 10.1023/A:1021127410300 10.1093/humupd/dmr008 10.1093/humrep/dei150 10.1186/1477-7827-9-85 10.1007/BF01133388 10.1016/S0015-0282(03)00544-2 10.1016/j.fertnstert.2013.09.007 10.1007/s00404-013-2794-z 10.1093/humupd/dms016 10.1056/NEJMoa1008095 10.1210/jcem-57-4-797 10.1210/er.2005-0015 10.2165/00003495-200464030-00005 10.1016/S0015-0282(03)00173-0 10.1016/j.fertnstert.2011.01.019 10.1093/oxfordjournals.humrep.a137287 10.1093/humupd/dmr039 10.1016/S0140-6736(07)60360-2 10.1210/jcem-58-2-378 10.1093/humrep/dem285 10.1093/oxfordjournals.humrep.a136136 10.1016/j.fertnstert.2010.01.069 10.1095/biolreprod.103.017772 10.1016/j.fertnstert.2010.09.023 10.1016/j.fertnstert.2008.08.011 10.1093/humrep/15.7.1490 10.1093/oxfordjournals.humrep.a019034 10.1007/s10815-010-9429-0 10.1016/S0015-0282(16)55430-2 10.1016/j.rbmo.2014.08.009 10.1016/j.fertnstert.2012.05.019 10.1016/S0015-0282(99)00458-6 10.1093/humrep/dei106 |
| ContentType | Journal Article |
| Copyright | 2015 John Wiley & Sons Ltd 2015 John Wiley & Sons Ltd. Copyright © 2016 John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2015 John Wiley & Sons Ltd – notice: 2015 John Wiley & Sons Ltd. – notice: Copyright © 2016 John Wiley & Sons Ltd |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP K9. NAPCQ 7X8 |
| DOI | 10.1111/cen.12983 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2265 |
| EndPage | 728 |
| ExternalDocumentID | 4009281921 26603821 10_1111_cen_12983 CEN12983 ark_67375_WNG_378PRV16_W |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NSFC funderid: 31071275; 81270749; 31101070 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 08P 0R~ 10A 1OB 1OC 29B 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AAQQT AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K REN RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QP AAMMB AEFGJ AGXDD AIDQK AIDYY K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c3913-76e7bca478bfe78fc926ef8b8a216269adbf4802ad85ce88f584a9d15c9a35b33 |
| IEDL.DBID | DR2 |
| ISSN | 0300-0664 |
| IngestDate | Fri Sep 05 09:21:26 EDT 2025 Wed Aug 13 07:05:12 EDT 2025 Thu Apr 03 06:56:22 EDT 2025 Tue Jul 01 01:33:14 EDT 2025 Thu Apr 24 23:03:26 EDT 2025 Wed Jan 22 16:56:44 EST 2025 Wed Oct 30 09:51:36 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2015 John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3913-76e7bca478bfe78fc926ef8b8a216269adbf4802ad85ce88f584a9d15c9a35b33 |
| Notes | ArticleID:CEN12983 ark:/67375/WNG-378PRV16-W istex:275EA3085515EE96669A138BE86349370AB1F195 NSFC - No. 31071275; No. 81270749; No. 31101070 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 26603821 |
| PQID | 1778101222 |
| PQPubID | 36523 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1779021945 proquest_journals_1778101222 pubmed_primary_26603821 crossref_primary_10_1111_cen_12983 crossref_citationtrail_10_1111_cen_12983 wiley_primary_10_1111_cen_12983_CEN12983 istex_primary_ark_67375_WNG_378PRV16_W |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-05 May 2016 2016-05-00 2016-May 20160501 |
| PublicationDateYYYYMMDD | 2016-05-01 |
| PublicationDate_xml | – month: 05 year: 2016 text: 2016-05 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | Clinical endocrinology (Oxford) |
| PublicationTitleAlternate | Clin Endocrinol |
| PublicationYear | 2016 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | Kuang, Y., Hong, Q., Chen, Q. et al. (2014) Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertility and Sterility, 101, 105-111. Lamb, J.D., Shen, S., McCulloch, C. et al. (2011) Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility, 95, 1655-1660. Baerwald, A.R., Adams, G.P. & Pierson, R.A. (2003) A new model for ovarian follicular development during the human menstrual cycle. Fertility and Sterility, 80, 116-122. Kuang, Y., Chen, Q., Hong, Q. et al. (2014) Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reproductive Biomedicine Online, 29, 684-691. Hohmann, F.P., Macklon, N.S. & Fauser, B.C. (2003) A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. Journal of Clinical Endocrinology and Metabolism, 88, 166-173. Papanikolaou, E.G., Verpoest, W., Fatemi, H. et al. (2011) A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertility and Sterility, 95, 1174-1177. Heijnen, E.M., Eijkemans, M.J., De Klerk, C. et al. (2007) A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet, 369, 743-749. Huisman, G.J., Fauser, B.C., Eijkemans, M.J. et al. (2000) Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture. Fertility and Sterility, 73, 117-122. Humaidan, P., Kol, S. & Papanikolaou, E.G. (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Human Reproduction Update, 17, 510-524. Liu, J.H. & Yen, S.S. (1983) Induction of midcycle gonadotropin surge by ovarian steroids in women: a critical evaluation. Journal of Clinical Endocrinology and Metabolism, 57, 797-802. Peluso, J.J. (2013) Progesterone receptor membrane component 1 and its role in ovarian follicle growth. Frontiers in Neuroscience, 7, 99. Maheshwari, A., Pandey, S., Shetty, A. et al. (2012) Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertility and Sterility, 98, 368-377. e361-369. Broekmans, F.J., Hompes, P.G., Lambalk, C.B. et al. (1996) Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. Human Reproduction, 11, 55-60. Baerwald, A.R., Adams, G.P. & Pierson, R.A. (2003) Characterization of ovarian follicular wave dynamics in women. Biology of Reproduction, 69, 1023-1031. Daya, S. (2000) Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization gamete intrafallopian transfer cycles. Cochrane Database Systematic Review, 2, CD001299. Nargund, G., Fauser, B.C., Macklon, N.S. et al. (2007) The ISMAAR proposal on terminology for ovarian stimulation for IVF. Human Reproduction, 22, 2801-2804. Davies, M.J., Moore, V.M., Willson, K.J. et al. (2012) Reproductive technologies and the risk of birth defects. New England Journal of Medicine, 366, 1803-1813. Bedoschi, G.M., de Albuquerque, F.O., Ferriani, R.A. et al. (2010) Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. Journal of Assisted Reproduction and Genetics, 27, 491-494. Romeu, A., Molina, I., Tresguerres, J.A. et al. (1995) Effect of recombinant human luteinizing hormone versus human chorionic gonadotrophin: effects on ovulation, embryo quality and transport, steroid balance and implantation in rabbits. Human Reproduction, 10, 1290-1296. Macklon, N.S., Stouffer, R.L., Giudice, L.C. et al. (2006) The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocrine Reviews, 27, 170-207. Baerwald, A.R., Adams, G.P. & Pierson, R.A. (2012) Ovarian antral folliculogenesis during the human menstrual cycle: a review. Human Reproduction Update, 18, 73-91. Papanikolaou, E.G., Polyzos, N.P., Humaidan, P. et al. (2011) Aromatase inhibitors in stimulated IVF cycles. Reproductive Biology and Endocrinology, 9, 85. Lainas, T., Zorzovilis, J., Petsas, G. et al. (2005) In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Human Reproduction, 20, 2426-2433. Gross, K.M., Matsumoto, A.M. & Bremner, W.J. (1987) Differential control of luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man. Journal of Clinical Endocrinology and Metabolism, 64, 675-680. Buendgen, N.K., Schultze-Mosgau, A., Cordes, T. et al. (2013) Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study. Archives of Gynecology and Obstetrics, 288, 901-904. Edgar, D.H. & Gook, D.A. (2012) A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos. Human Reproduction Update, 18, 536-554. Al-Inany, H., Azab, H., El-Khayat, W. et al. (2010) The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial. Fertility and Sterility, 94, 2167-2171. Kolibianakis, E.M., Schultze-Mosgau, A., Schroer, A. et al. (2005) A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction, 20, 2887-2892. Molina, I., Pla, M., Vicente, J.S. et al. (1991) Induction of ovulation in rabbits with pure urinary luteinizing hormone and human chorionic gonadotrophin: comparison of oocyte and embryo quality. Human Reproduction, 6, 1449-1452. Romeu, A., Monzo, A., Peiro, T. et al. (1997) Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles. Journal of Assisted Reproduction and Genetics, 14, 518-524. Cummins, J.M., Breen, T.M., Harrison, K.L. et al. (1986) A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. Journal of In Vitro Fertilization and Embryo Transfer, 3, 284-295. Ludwig, M., Doody, K.J. & Doody, K.M. (2003) Use of recombinant human chorionic gonadotropin in ovulation induction. Fertility and Sterility, 79, 1051-1059. Huirne, J.A., Lambalk, C.B., van Loenen, A.C. et al. (2004) Contemporary pharmacological manipulation in assisted reproduction. Drugs, 64, 297-322. Hughes, E.G., Fedorkow, D.M., Daya, S. et al. (1992) The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility, 58, 888-896. Verberg, M.F., Macklon, N.S., Nargund, G. et al. (2009) Mild ovarian stimulation for IVF. Human Reproduction Update, 15, 13-29. von Wolff, M., Thaler, C.J., Frambach, T. et al. (2009) Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertility and Sterility, 92, 1360-1365. Soules, M.R., Steiner, R.A., Clifton, D.K. et al. (1984) Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. Journal of Clinical Endocrinology and Metabolism, 58, 378-383. Borm, G. & Mannaerts, B. (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Human Reproduction, 15, 1490-1498. 2004; 64 2007; 369 2003; 80 2012; 366 1995; 10 2013; 288 2003; 79 2000; 73 2005; 20 2000; 2 2012; 18 1992; 58 2014; 29 2011; 17 2013; 7 1983; 57 2012; 98 1991; 6 1996; 11 2011; 9 2010; 27 1987; 64 2009; 92 1984; 58 2000; 15 2006; 27 1986; 3 1997; 14 2011; 95 2003; 69 2007; 22 2009; 15 2014; 101 2003; 88 2010; 94 e_1_2_8_28_1 Molina I. (e_1_2_8_29_1) 1991; 6 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 Daya S. (e_1_2_8_3_1) 2000; 2 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
| References_xml | – reference: Cummins, J.M., Breen, T.M., Harrison, K.L. et al. (1986) A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. Journal of In Vitro Fertilization and Embryo Transfer, 3, 284-295. – reference: Peluso, J.J. (2013) Progesterone receptor membrane component 1 and its role in ovarian follicle growth. Frontiers in Neuroscience, 7, 99. – reference: Daya, S. (2000) Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization gamete intrafallopian transfer cycles. Cochrane Database Systematic Review, 2, CD001299. – reference: Romeu, A., Monzo, A., Peiro, T. et al. (1997) Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles. Journal of Assisted Reproduction and Genetics, 14, 518-524. – reference: Borm, G. & Mannaerts, B. (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Human Reproduction, 15, 1490-1498. – reference: Gross, K.M., Matsumoto, A.M. & Bremner, W.J. (1987) Differential control of luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man. Journal of Clinical Endocrinology and Metabolism, 64, 675-680. – reference: Nargund, G., Fauser, B.C., Macklon, N.S. et al. (2007) The ISMAAR proposal on terminology for ovarian stimulation for IVF. Human Reproduction, 22, 2801-2804. – reference: Maheshwari, A., Pandey, S., Shetty, A. et al. (2012) Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertility and Sterility, 98, 368-377. e361-369. – reference: Papanikolaou, E.G., Verpoest, W., Fatemi, H. et al. (2011) A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertility and Sterility, 95, 1174-1177. – reference: Lamb, J.D., Shen, S., McCulloch, C. et al. (2011) Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility, 95, 1655-1660. – reference: Ludwig, M., Doody, K.J. & Doody, K.M. (2003) Use of recombinant human chorionic gonadotropin in ovulation induction. Fertility and Sterility, 79, 1051-1059. – reference: Edgar, D.H. & Gook, D.A. (2012) A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos. Human Reproduction Update, 18, 536-554. – reference: Huisman, G.J., Fauser, B.C., Eijkemans, M.J. et al. (2000) Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture. Fertility and Sterility, 73, 117-122. – reference: Broekmans, F.J., Hompes, P.G., Lambalk, C.B. et al. (1996) Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. Human Reproduction, 11, 55-60. – reference: Baerwald, A.R., Adams, G.P. & Pierson, R.A. (2003) Characterization of ovarian follicular wave dynamics in women. Biology of Reproduction, 69, 1023-1031. – reference: Verberg, M.F., Macklon, N.S., Nargund, G. et al. (2009) Mild ovarian stimulation for IVF. Human Reproduction Update, 15, 13-29. – reference: Buendgen, N.K., Schultze-Mosgau, A., Cordes, T. et al. (2013) Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study. Archives of Gynecology and Obstetrics, 288, 901-904. – reference: Baerwald, A.R., Adams, G.P. & Pierson, R.A. (2012) Ovarian antral folliculogenesis during the human menstrual cycle: a review. Human Reproduction Update, 18, 73-91. – reference: Soules, M.R., Steiner, R.A., Clifton, D.K. et al. (1984) Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. Journal of Clinical Endocrinology and Metabolism, 58, 378-383. – reference: Davies, M.J., Moore, V.M., Willson, K.J. et al. (2012) Reproductive technologies and the risk of birth defects. New England Journal of Medicine, 366, 1803-1813. – reference: Romeu, A., Molina, I., Tresguerres, J.A. et al. (1995) Effect of recombinant human luteinizing hormone versus human chorionic gonadotrophin: effects on ovulation, embryo quality and transport, steroid balance and implantation in rabbits. Human Reproduction, 10, 1290-1296. – reference: Bedoschi, G.M., de Albuquerque, F.O., Ferriani, R.A. et al. (2010) Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. Journal of Assisted Reproduction and Genetics, 27, 491-494. – reference: Humaidan, P., Kol, S. & Papanikolaou, E.G. (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Human Reproduction Update, 17, 510-524. – reference: Heijnen, E.M., Eijkemans, M.J., De Klerk, C. et al. (2007) A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet, 369, 743-749. – reference: Baerwald, A.R., Adams, G.P. & Pierson, R.A. (2003) A new model for ovarian follicular development during the human menstrual cycle. Fertility and Sterility, 80, 116-122. – reference: Kuang, Y., Hong, Q., Chen, Q. et al. (2014) Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertility and Sterility, 101, 105-111. – reference: Hohmann, F.P., Macklon, N.S. & Fauser, B.C. (2003) A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. Journal of Clinical Endocrinology and Metabolism, 88, 166-173. – reference: Kolibianakis, E.M., Schultze-Mosgau, A., Schroer, A. et al. (2005) A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction, 20, 2887-2892. – reference: von Wolff, M., Thaler, C.J., Frambach, T. et al. (2009) Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertility and Sterility, 92, 1360-1365. – reference: Al-Inany, H., Azab, H., El-Khayat, W. et al. (2010) The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial. Fertility and Sterility, 94, 2167-2171. – reference: Hughes, E.G., Fedorkow, D.M., Daya, S. et al. (1992) The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility, 58, 888-896. – reference: Papanikolaou, E.G., Polyzos, N.P., Humaidan, P. et al. (2011) Aromatase inhibitors in stimulated IVF cycles. Reproductive Biology and Endocrinology, 9, 85. – reference: Liu, J.H. & Yen, S.S. (1983) Induction of midcycle gonadotropin surge by ovarian steroids in women: a critical evaluation. Journal of Clinical Endocrinology and Metabolism, 57, 797-802. – reference: Molina, I., Pla, M., Vicente, J.S. et al. (1991) Induction of ovulation in rabbits with pure urinary luteinizing hormone and human chorionic gonadotrophin: comparison of oocyte and embryo quality. Human Reproduction, 6, 1449-1452. – reference: Lainas, T., Zorzovilis, J., Petsas, G. et al. (2005) In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Human Reproduction, 20, 2426-2433. – reference: Kuang, Y., Chen, Q., Hong, Q. et al. (2014) Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reproductive Biomedicine Online, 29, 684-691. – reference: Macklon, N.S., Stouffer, R.L., Giudice, L.C. et al. (2006) The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocrine Reviews, 27, 170-207. – reference: Huirne, J.A., Lambalk, C.B., van Loenen, A.C. et al. (2004) Contemporary pharmacological manipulation in assisted reproduction. Drugs, 64, 297-322. – volume: 101 start-page: 105 year: 2014 end-page: 111 article-title: Luteal‐phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen‐thawed embryo transfer cycles publication-title: Fertility and Sterility – volume: 64 start-page: 675 year: 1987 end-page: 680 article-title: Differential control of luteinizing hormone and follicle‐stimulating hormone secretion by luteinizing hormone‐releasing hormone pulse frequency in man publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 27 start-page: 170 year: 2006 end-page: 207 article-title: The science behind 25 years of ovarian stimulation for in vitro fertilization publication-title: Endocrine Reviews – volume: 58 start-page: 378 year: 1984 end-page: 383 article-title: Progesterone modulation of pulsatile luteinizing hormone secretion in normal women publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 95 start-page: 1174 year: 2011 end-page: 1177 article-title: A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin‐releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study publication-title: Fertility and Sterility – volume: 58 start-page: 888 year: 1992 end-page: 896 article-title: The routine use of gonadotropin‐releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta‐analysis of randomized controlled trials publication-title: Fertility and Sterility – volume: 94 start-page: 2167 year: 2010 end-page: 2171 article-title: The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial publication-title: Fertility and Sterility – volume: 14 start-page: 518 year: 1997 end-page: 524 article-title: Endogenous LH surge versus hCG as ovulation trigger after low‐dose highly purified FSH in IUI: a comparison of 761 cycles publication-title: Journal of Assisted Reproduction and Genetics – volume: 11 start-page: 55 year: 1996 end-page: 60 article-title: Short term pituitary desensitization: effects of different doses of the gonadotrophin‐releasing hormone agonist triptorelin publication-title: Human Reproduction – volume: 2 start-page: CD001299 year: 2000 article-title: Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization gamete intrafallopian transfer cycles publication-title: Cochrane Database Systematic Review – volume: 366 start-page: 1803 year: 2012 end-page: 1813 article-title: Reproductive technologies and the risk of birth defects publication-title: New England Journal of Medicine – volume: 27 start-page: 491 year: 2010 end-page: 494 article-title: Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature publication-title: Journal of Assisted Reproduction and Genetics – volume: 15 start-page: 13 year: 2009 end-page: 29 article-title: Mild ovarian stimulation for IVF publication-title: Human Reproduction Update – volume: 80 start-page: 116 year: 2003 end-page: 122 article-title: A new model for ovarian follicular development during the human menstrual cycle publication-title: Fertility and Sterility – volume: 288 start-page: 901 year: 2013 end-page: 904 article-title: Initiation of ovarian stimulation independent of the menstrual cycle: a case–control study publication-title: Archives of Gynecology and Obstetrics – volume: 92 start-page: 1360 year: 2009 end-page: 1365 article-title: Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase publication-title: Fertility and Sterility – volume: 9 start-page: 85 year: 2011 article-title: Aromatase inhibitors in stimulated IVF cycles publication-title: Reproductive Biology and Endocrinology – volume: 79 start-page: 1051 year: 2003 end-page: 1059 article-title: Use of recombinant human chorionic gonadotropin in ovulation induction publication-title: Fertility and Sterility – volume: 7 start-page: 99 year: 2013 article-title: Progesterone receptor membrane component 1 and its role in ovarian follicle growth publication-title: Frontiers in Neuroscience – volume: 6 start-page: 1449 year: 1991 end-page: 1452 article-title: Induction of ovulation in rabbits with pure urinary luteinizing hormone and human chorionic gonadotrophin: comparison of oocyte and embryo quality publication-title: Human Reproduction – volume: 73 start-page: 117 year: 2000 end-page: 122 article-title: Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture publication-title: Fertility and Sterility – volume: 3 start-page: 284 year: 1986 end-page: 295 article-title: A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality publication-title: Journal of In Vitro Fertilization and Embryo Transfer – volume: 18 start-page: 73 year: 2012 end-page: 91 article-title: Ovarian antral folliculogenesis during the human menstrual cycle: a review publication-title: Human Reproduction Update – volume: 18 start-page: 536 year: 2012 end-page: 554 article-title: A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos publication-title: Human Reproduction Update – volume: 57 start-page: 797 year: 1983 end-page: 802 article-title: Induction of midcycle gonadotropin surge by ovarian steroids in women: a critical evaluation publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 15 start-page: 1490 year: 2000 end-page: 1498 article-title: Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group publication-title: Human Reproduction – volume: 64 start-page: 297 year: 2004 end-page: 322 article-title: Contemporary pharmacological manipulation in assisted reproduction publication-title: Drugs – volume: 369 start-page: 743 year: 2007 end-page: 749 article-title: A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial publication-title: Lancet – volume: 20 start-page: 2887 year: 2005 end-page: 2892 article-title: A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists publication-title: Human Reproduction – volume: 95 start-page: 1655 year: 2011 end-page: 1660 article-title: Follicle‐stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double‐blind, placebo‐controlled trial publication-title: Fertility and Sterility – volume: 88 start-page: 166 year: 2003 end-page: 173 article-title: A randomized comparison of two ovarian stimulation protocols with gonadotropin‐releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle‐stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 22 start-page: 2801 year: 2007 end-page: 2804 article-title: The ISMAAR proposal on terminology for ovarian stimulation for IVF publication-title: Human Reproduction – volume: 20 start-page: 2426 year: 2005 end-page: 2433 article-title: In a flexible antagonist protocol, earlier, criteria‐based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF publication-title: Human Reproduction – volume: 69 start-page: 1023 year: 2003 end-page: 1031 article-title: Characterization of ovarian follicular wave dynamics in women publication-title: Biology of Reproduction – volume: 10 start-page: 1290 year: 1995 end-page: 1296 article-title: Effect of recombinant human luteinizing hormone versus human chorionic gonadotrophin: effects on ovulation, embryo quality and transport, steroid balance and implantation in rabbits publication-title: Human Reproduction – volume: 17 start-page: 510 year: 2011 end-page: 524 article-title: GnRH agonist for triggering of final oocyte maturation: time for a change of practice? publication-title: Human Reproduction Update – volume: 98 start-page: 368 year: 2012 end-page: 377 article-title: Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta‐analysis publication-title: Fertility and Sterility – volume: 29 start-page: 684 year: 2014 end-page: 691 article-title: Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol) publication-title: Reproductive Biomedicine Online – ident: e_1_2_8_35_1 doi: 10.1210/jcem-64-4-675 – ident: e_1_2_8_8_1 doi: 10.1093/humupd/dmn056 – ident: e_1_2_8_15_1 doi: 10.1210/jc.2002-020788 – ident: e_1_2_8_38_1 doi: 10.3389/fnins.2013.00099 – ident: e_1_2_8_31_1 doi: 10.1023/A:1021127410300 – ident: e_1_2_8_25_1 doi: 10.1093/humupd/dmr008 – ident: e_1_2_8_23_1 doi: 10.1093/humrep/dei150 – ident: e_1_2_8_21_1 doi: 10.1186/1477-7827-9-85 – ident: e_1_2_8_19_1 doi: 10.1007/BF01133388 – ident: e_1_2_8_27_1 doi: 10.1016/S0015-0282(03)00544-2 – ident: e_1_2_8_13_1 doi: 10.1016/j.fertnstert.2013.09.007 – ident: e_1_2_8_12_1 doi: 10.1007/s00404-013-2794-z – ident: e_1_2_8_20_1 doi: 10.1093/humupd/dms016 – ident: e_1_2_8_37_1 doi: 10.1056/NEJMoa1008095 – ident: e_1_2_8_36_1 doi: 10.1210/jcem-57-4-797 – ident: e_1_2_8_2_1 doi: 10.1210/er.2005-0015 – ident: e_1_2_8_4_1 doi: 10.2165/00003495-200464030-00005 – ident: e_1_2_8_22_1 doi: 10.1016/S0015-0282(03)00173-0 – ident: e_1_2_8_28_1 doi: 10.1016/j.fertnstert.2011.01.019 – volume: 6 start-page: 1449 year: 1991 ident: e_1_2_8_29_1 article-title: Induction of ovulation in rabbits with pure urinary luteinizing hormone and human chorionic gonadotrophin: comparison of oocyte and embryo quality publication-title: Human Reproduction doi: 10.1093/oxfordjournals.humrep.a137287 – ident: e_1_2_8_9_1 doi: 10.1093/humupd/dmr039 – ident: e_1_2_8_7_1 doi: 10.1016/S0140-6736(07)60360-2 – ident: e_1_2_8_34_1 doi: 10.1210/jcem-58-2-378 – ident: e_1_2_8_16_1 doi: 10.1093/humrep/dem285 – ident: e_1_2_8_30_1 doi: 10.1093/oxfordjournals.humrep.a136136 – ident: e_1_2_8_18_1 doi: 10.1016/j.fertnstert.2010.01.069 – ident: e_1_2_8_26_1 doi: 10.1095/biolreprod.103.017772 – volume: 2 start-page: CD001299 year: 2000 ident: e_1_2_8_3_1 article-title: Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization gamete intrafallopian transfer cycles publication-title: Cochrane Database Systematic Review – ident: e_1_2_8_24_1 doi: 10.1016/j.fertnstert.2010.09.023 – ident: e_1_2_8_10_1 doi: 10.1016/j.fertnstert.2008.08.011 – ident: e_1_2_8_32_1 doi: 10.1093/humrep/15.7.1490 – ident: e_1_2_8_6_1 doi: 10.1093/oxfordjournals.humrep.a019034 – ident: e_1_2_8_11_1 doi: 10.1007/s10815-010-9429-0 – ident: e_1_2_8_5_1 doi: 10.1016/S0015-0282(16)55430-2 – ident: e_1_2_8_33_1 doi: 10.1016/j.rbmo.2014.08.009 – ident: e_1_2_8_39_1 doi: 10.1016/j.fertnstert.2012.05.019 – ident: e_1_2_8_14_1 doi: 10.1016/S0015-0282(99)00458-6 – ident: e_1_2_8_17_1 doi: 10.1093/humrep/dei106 |
| SSID | ssj0005807 |
| Score | 2.4464252 |
| Snippet | Summary
Objective
We have previously reported a new luteal‐phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to... We have previously reported a new luteal-phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to systematically... Summary Objective We have previously reported a new luteal-phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to... OBJECTIVEWe have previously reported a new luteal-phase ovarian stimulation (LPS) strategy for infertility treatment. The purpose of this study was to... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 720 |
| SubjectTerms | Adult Embryo Implantation Female Fertilization in Vitro - methods Follicular Phase - physiology Humans Infant, Newborn Logistic Models Luteal Phase - physiology Oocytes - cytology Oocytes - physiology Ovarian Reserve - physiology Ovulation Induction - methods Pregnancy Pregnancy Outcome Pregnancy Rate Retrospective Studies |
| Title | Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study |
| URI | https://api.istex.fr/ark:/67375/WNG-378PRV16-W/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcen.12983 https://www.ncbi.nlm.nih.gov/pubmed/26603821 https://www.proquest.com/docview/1778101222 https://www.proquest.com/docview/1779021945 |
| Volume | 84 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFD4sK4gv3i_VVaKI-NJhmrRJqk-y7LiKO8jiXh6EkltRduwsnc4gPvkT_A3-NH-JJ-lld2UE8a3QU5qm5_IlOec7AE-501bqksdKGRqn1iaxLsssVmNBHcYUk4V2b3tTvnuQvj3OjjfgZV8L0_JDDBtu3jKCv_YGrvTinJEbV40wWEnP9OlztTwg2j-jjsq6UmnmK6c5TztWIZ_FMzx5IRZd8tP6dR3QvIhbQ-CZXIOP_ZDbfJOT0bLRI_PtDzbH__ym63C1A6TkVatBN2DDVTfh8l535H4Lfr5boh7Mfn3_cfoJIx6Zr3B1rSqCruFL1_qLrBbkfPb6WpnPFek4XBfEb_6SyqPlM1lfBlWvHAmZ784SBNPkzeHkBVFk5rPVUaCp531hKPGNfeuGBHbc23Aw2fmwvRt3jR1iw_KExYI7oY1KBWqJE7I0OeWulFoqmuACK1dWl6kcU2VlZpyUJaIkldskM7limWbsDmxW88rdA4JOyWlmqRKlTVk5lkZr40FL7jAAWxXB8_4XF6ZjPffNN2ZFv_rBOS_CnEfwZBA9bak-1gk9C3oySKj6xOfGiaw4mr4umJDv9w8TXhxFsNUrUtG5hUWRCBEI1SiN4PFwGw3an9Koys2XQSZHI8nTLIK7rQIOL0M0NWaSJvhVQY3-Ps5ie2caLu7_u-gDuIJwkLfpnFuw2dRL9xAhV6MfBdv6DRT8K-c |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB2VVgJeuF8CBQxCiJesNnESO4gXVLpsYXeFqt5eKst2HIG6ZKtsdoV44hP4Bj6NL2HsXNqiRUK8RcpEcZy5HNszZwCeJ0ZlXOWJL6UO_SjLAl_leezLPgsNxhQdu3Zv40ky3I_eH8VHa_C6rYWp-SG6DTdrGc5fWwO3G9LnrFyboofRitNLsGE7eluzfLt7Rh4VN8XS1NZOJ0nU8ArZPJ7u0QvRaMNO7NdVUPMicnWhZ3AdjttB1xknJ71FpXr62x98jv_7VTfgWoNJyZtaiW7CmiluweVxc-p-G36OFqgK01_ff5x-wqBHZktcYMuCoHf40nT_Iss5OZ_AvlLmc0EaGtc5sfu_pLCA-UzWVkKVS0Nc8rvJCOJpsnMweEUkmdqEdRSoyllbG0psb9-yIo4g9w7sD7b3toZ-09vB1zQNqM8Sw5SWEUNFMYznOg0Tk3PFZRjgGiuVmcoj3g9lxmNtOM8RKMk0C2KdShorSu_CejErzH0g6JeMolkoWZ5FNO9zrZS2uCU1GIMz6cHL9h8L3RCf2_4bU9EugHDOhZtzD551oqc128cqoRdOUToJWZ7Y9DgWi8PJO0EZ_7h7ECTi0IPNVpNE4xnmImDMcaqFoQdPu9to0_agRhZmtnAyKdpJGsUe3Ks1sHsZAqo-5WGAX-X06O_jFFvbE3fx4N9Fn8CV4d54JEY7kw8P4Sqiw6TO7tyE9apcmEeIwCr12Bnab53mMAA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ZbtQwFLVKK1W8sC-BAgYhxEtGSZzYDjyhtkML7aiq6PKAZHmLQB0yo0xmhHjiE_gGPo0v4dpZ2qJBQrxFyo3iOHc5tu89F6Hn1CrDVUFDKXUSpsbEoSqKLJQRSyzEFJ35dm_7I7pzlL47zU5X0OuuFqbhh-g33JxleH_tDHxqigtGrm05gGDFyRW0ltKIu5XX1uE5d1TW1koTVzpNadrSCrk0nv7RS8Fozc3r12VI8zJw9ZFneB197MbcJJycDea1Guhvf9A5_udH3UDXWkSK3zQqdBOt2PIWWt9vz9xvo597c1CE8a_vP6afIOThyQKW17LE4Bu-tL2_8GKGL6avL5X5XOKWxHWG3e4vLh1cPpd1dVDVwmKf-m4NBjSNd4-Hr7DEY5euDgJ1NekqQ7Hr7FvV2NPj3kFHw-0Pmzth29kh1CSPScioZUrLlIGaWMYLnSfUFlxxmcSwwsqlUUXKo0QanmnLeQEwSeYmznQuSaYIuYtWy0lp7yMMXskqYhLJCpOSIuJaKe1QS24hAhsZoJfdLxa6pT133TfGolv-wJwLP-cBetaLThuuj2VCL7ye9BKyOnPJcSwTJ6O3gjB-cHgcU3ESoI1OkUTrF2YiZswzqiVJgJ72t8Gi3TGNLO1k7mVysJI8zQJ0r1HA_mUApyLCkxi-yqvR38cpNrdH_uLBv4s-QesHW0Oxtzt6_xBdBWhIm9TODbRaV3P7COBXrR57M_sNFqouuA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Luteal-phase+ovarian+stimulation+vs+conventional+ovarian+stimulation+in+patients+with+normal+ovarian+reserve+treated+for+IVF%3A+a+large+retrospective+cohort+study&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Wang%2C+Ningling&rft.au=Wang%2C+Yun&rft.au=Chen%2C+Qiuju&rft.au=Dong%2C+Jing&rft.date=2016-05-01&rft.eissn=1365-2265&rft.volume=84&rft.issue=5&rft.spage=720&rft.epage=728&rft_id=info:doi/10.1111%2Fcen.12983&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon |